Digital health company Ro has announced a collaboration with pharmaceutical giant Eli Lilly and Company (NYSE:LLY).
As a result, Hims & Hers Health shares felt about 4% in pre-market trade.
The partnership aims to streamline the process for Ro patients to obtain Zepbound (tirzepatide) single-dose vials through an integration with LillyDirect, a self-pay pharmacy channel. This initiative is designed to facilitate the delivery of FDA-approved obesity medication directly to patients at a self-pay price.
Patrik Jonsson, Lilly's executive vice president and president of Lilly Cardiometabolic Health and Lilly USA, stated that the availability of Zepbound single-dose vials via LillyDirect is intended to expand access to obesity treatments that have undergone rigorous testing and received FDA approval. Jonsson emphasized the company's commitment to breaking down barriers to safe and effective treatment options.
Zach Reitano, co-founder and CEO of Ro, highlighted the significance of the integration, which allows patients to access the dual GIP and GLP-1 receptor agonist without needing to leave the Ro app or their homes. Reitano expressed Ro's dedication to advocating for patient needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.